A ricin-based peptide BRIP from Hordeum vulgare inhibits Mpro of SARS-CoV-2

Sci Rep. 2022 Jul 27;12(1):12802. doi: 10.1038/s41598-022-15977-y.

Abstract

COVID-19 pandemic caused by SARS-CoV-2 led to the research aiming to find the inhibitors of this virus. Towards this world problem, an attempt was made to identify SARS-CoV-2 main protease (Mpro) inhibitory peptides from ricin domains. The ricin-based peptide from barley (BRIP) was able to inhibit Mpro in vitro with an IC50 of 0.52 nM. Its low and no cytotoxicity upto 50 µM suggested its therapeutic potential against SARS-CoV-2. The most favorable binding site on Mpro was identified by molecular docking and steered molecular dynamics (MD) simulations. The Mpro-BRIP interactions were further investigated by evaluating the trajectories for microsecond timescale MD simulations. The structural parameters of Mpro-BRIP complex were stable, and the presence of oppositely charged surfaces on the binding interface of BRIP and Mpro complex further contributed to the overall stability of the protein-peptide complex. Among the components of thermodynamic binding free energy, Van der Waals and electrostatic contributions were most favorable for complex formation. Our findings provide novel insight into the area of inhibitor development against COVID-19.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology
  • COVID-19 Drug Treatment*
  • Hordeum* / metabolism
  • Humans
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation
  • Pandemics
  • Peptides / pharmacology
  • Protease Inhibitors / pharmacology
  • Ricin* / metabolism
  • Ricin* / pharmacology
  • SARS-CoV-2
  • Viral Nonstructural Proteins / metabolism

Substances

  • Antiviral Agents
  • Peptides
  • Protease Inhibitors
  • Viral Nonstructural Proteins
  • Ricin